Importance of iron chelation in free radical-induced oxidative stress and human disease

Current Pharmaceutical Design

Volumn 17, Issue 31, 2011, Pages 3460-3473

  Jomova, Klaudia ^a   Valko, Marian ^a,b  

^a The Philosopher University in Nitra Geoinformatics and Regional Development   (Slovakia)

^b SLOVAK UNIVERSITY OF TECHNOLOGY   (Slovakia)

Author keywords

Aging; Fenton reaction; Iron homeostasis; Iron toxicity; Metal chelators; Reactive oxygen species (ros); Redox active metals

Indexed keywords

2,8 DIHYDROXYADENINE; 8 HYDROXYGUANINE; ALPHA TOCOPHEROL; APOPTOSIS SIGNAL REGULATING KINASE 1; ASCORBIC ACID; BONE MORPHOGENETIC PROTEIN 6; CYSTEINE; EPICATECHIN; FREE RADICAL; GLUTATHIONE; GLUTATHIONE DISULFIDE; HEMOGLOBIN; HESPERETIN; HYPOXIA INDUCIBLE FACTOR; I KAPPA B; IRON REGULATORY FACTOR; NARINGENIN; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; QUERCETIN; THIOREDOXIN;

AGING; APOPTOSIS; FRIEDREICH ATAXIA; HUMAN; HUNTINGTON CHOREA; IRON ABSORPTION; IRON BALANCE; IRON CHELATION; IRON STORAGE; NEOPLASM; OXIDATIVE STRESS; PRIORITY JOURNAL; REDOX STRESS; REVIEW; SEPTIC SHOCK; THALASSEMIA; THERMODYNAMICS;

FREE RADICALS; HUMANS; IRON; NEURODEGENERATIVE DISEASES; OXIDATION-REDUCTION; OXIDATIVE STRESS;

EID: 80055078417     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211798072463     Document Type: Review

References (164)

1. Valko M, Morris H, Cronin MTD. Met-aletal/et-als, toxicity and oxidative stress. Curr Med Chem 2005; 12(10): 1161-208.
2. Ye H, Rouault TA. Human Iron-Sulfur Cluster Assembly, CellularIron Homeostasis, and Disease. Biochemistry 2010; 49(24): 4945-56.
3. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independentprognostic factor for survival in patients with cancer: a systemic,quantitative review. Cancer. 2001; 91(12): 2214-21.
4. Whittington CA, Kowdley KV. Review article: haemochromatosis. Aliment Pharmacol Ther. 2002; 16(12): 1963-75.
5. Kell DB. Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics. 2009; 2: 2.
6. Crichton RR, Ward RJ. An overview of iron metabolism: molecu-lar and cellular criteria for the selection of iron chelators. Curr Med Chem. 2003; 10(12): 997-1004.
7. Prousek J. Fenton chemistry in biology and medicine. Pure Appl Chem 2007; 79, 2325-38.
8. Kell DB. Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples. Arch Toxicol. 2010; 84(11): 825-89.
9. Rhodes CJ, Toxicology of the Human Environment: The Critical Role of Free Radicals London: Taylor and Francis, 2000 [10] Buettner GR. The pecking order of free radicals and antioxidants:lipid peroxidation, alpha-tocopherol, and ascorbate. Arch Biochem Biophys 1993; 300(2): 535-43.
10. Butler J, Hoey BM. The one-electron reduction potential of several substrates can be related to their reduction rates by cytochrome P-450 reductase. Biochim Biophys Acta 1993; 1161(1): 73-8.
11. Hammes GG, Physical chemistry for the biological sciences, John Wiley & Sons, 2007
12. th Edition, Wiley & Sons, 2005
13. Schafer FQ, Buettner GR. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med. 2001; 30(11): 1191-212.
14. Filomeni G, Ciriolo MR. Redox control of apoptosis: an update.Antioxid Redox Signal 2006; 8(11-12): 2187-92.
15. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medi-cine, Oxford University Press 4th Edition, 2007
16. Valko M, Leibfritz D, Moncol J, Cronin MTD, Mazur M, Telser J.Free radicals and antioxidants in normal physiological functionsand human disease. Int J Biochem Cell Biol 2007; 39(1): 44-84.
17. Trachootham D, Lu W, Ogasawara MA, Nilsa RD, Huang P.Redox regulation of cell survival. Antioxid Redox Signal 2008;10(8): 1343-74.
18. Miller LT, Watson WH, Kirlin WG, Ziegler TR, and Jones DP.Oxidation of the glutathione/glutathione disulfide redox state is induced by cysteine deficiency in human colon carcinoma HT29 cells. J Nutr 2002; 132: 2303-6.
19. Jones DP, Carlson JL, Mody VC, Cai J, Lynn MJ, Sternberg P.Redox state of glutathione in human plasma. Free Radic Biol Med 2000; 28(4): 625-35.
20. Tsuyuki S, Yamauchi A, Nakamura H, et al. N-acetylcysteine improves cytotoxic activity of cirrhotic rat liver-associated mono-nuclear cells. Int Immunol. 1998; 10(10): 1501-8.
21. Jonas CR, Puckett AB, Jones DP, et al. Plasma antioxidant status after high-dose chemotherapy: a randomized trial of parenteral nu-trition in bone marrow transplantation patients. Am J Clin Nutr.2000; 72(1): 181-9.
22. Koháryová M, Kolárová M. Oxidative stress and thioredoxinsystem. Gen Physiol Biophys. 2008; 27(2): 71-84.
23. Haendeler J, Hoffmann J, Tischler V, Berk BC, Zeiher AM,Dimmeler S. Redox regulatory and anti-apoptotic functions of thi-oredoxin depend on S-nitrosylation at cysteine 69. Nat Cell Biol 2002; 4(10): 743-9.
24. Nkabyo YS, Ziegler TR, Gu LH, Watson WH, Jones DP. Glu-tathione and thioredoxin redox during differentiation in human co-lon epithelial (Caco-2) cells. Am J Physiol Gastrointest Liver Physiol. 2002; 283(6): G1352-9.
25. Go YM, Jones DP. Redox control systems in the nucleus: mecha-nisms and functions. Antioxid Redox Signal 2010; 13(4): 489-509.
26. Andrews NC, Schmidt PJ. Iron homeostasis. Annu Rev Physiol.2007; 69: 69-85.
27. Thomas C, Mackey MM, Diaz AA, Cox DP. Hydroxyl radical is produced via the Fenton reaction in submitochondrial particles un-der oxidative stress: implications for diseases associated with iron accumulation. Redox Rep 2009; 14(3): 102-8.
28. Wang J, Pantopoulos K. Regulation of cellular iron metabolism.Biochem. J 2011; 434: 365-81.
29. Nemeth E, Ganz T. Regulation of Iron Metabolism by Hepcidin. Annu Rev Nutr 2006; 26: 323-42.
30. Mackenzie EL, Iwasaki K, Tsuji Y., Intracellular Iron Transport and Storage: From molecular Mechanisms to Health Implications. An-tioxidants & Redox Signaling 2008; 10(6): 997-1030.
31. Knutson MD. Iron-Sensing Proteins that Regulate Hepcidin and Enteric Iron Absorption. Annu. Rev. Nutr 2010; 30: 71-149.
32. Gunshin H, Mackenzie B, Berger UV, et al Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 1997; 388: 482-88.
33. Keyse SM, Tyrrell RM. Heme oxygenase is the major 32-kDa stress protein induced in human skin fibroblasts by UVA radiation, hydrogen peroxide, and sodium arsenite. Proc Natl Acad Sci USA 1989; 86: 99-10
34. Espósito BP, Epsztejn S, Breuer W, and Cabantchik ZI. A Review of Fluorescence Methods for Assessing Labile Iron in Cells and Biological Fluids. Analytical Biochemistry 2002; 304: 1-18.
35. Kakhlon OR and Cabantchik ZI. The Labile Iron Pool:Characterisation, Measurement, and Participation in Cellular Processes. Free Radic Biol Med 2002; 33 (8): 1037-46.
36. Chasteen ND, and Harrison PM. Mineralization in Ferritin: An Efficient Means of Iron Storage. Journal of Structural Biology 1999; 126: 182-94.
37. Bou-Abdallah F. The iron redox and hydrolysis chemistry of the ferritins. Biochimica et Biophysica Acta 2010; 1800: 719-31.
38. Arosio P, Ingrassia R, Cavadini P. Ferritins: A family of molecules for iron storage, antioxidation and more Biochimica et Biophysica Acta 2009; 1790: 589-99.
39. Bou-Abdallah F, Arosio P, Levi S, Janus-Chandler CH, Chasteen ND. Defining metal ion inhibitor interactions with recombinant human H- and L-chain ferritins and site-directed variants: an isothermal titration calorimetry study. J Biol Inorg Chem 2003; 8: 489-97.
40. Levi S, Santambrogio P, Corsi B, Cozzi A, Arosio P. Evidence that residues exposed on the three-fold channels have active roles in the mechanism of ferritin iron incorporation Biochem. J 1996; 317:467-73.
41. Santambrogio P, Levi S, Cozzi A, Corsi B, Arosio P., Evidence that the specificity of iron incorporation into homopolymers of human ferritin L- and H-chains is conferred by the nucleation and ferroxidase centres. Biochem. J 1996; 314: 139-44.
42. Liu X, Theil E. Ferritins: dynamic management of biological iron and oxygen chemistry. Acc. Chem. Res 2005; 38: 167-75.
43. Shi H, Bencze KZ, Stemmler TL, Philpott CC. A cytosolic iron chaperone that delivers iron to ferritin. Science 2008; 320: 10-1207.
44. Subramanian P, Rodrigues AV, Ghimire-Rijal S, Stemmler TL. Iron chaperones for mitochondrial Fe-S cluster biosynthesis and ferritin iron storage. Current Opinion in Chemical Biology 2011;15: 312-8.
45. Bou-Abdallah F, Biasiotto G, Arosio P, Chasteen ND. The Putative "Nucleation Site" in Human H-Chain Ferritin Is Not Required for Mineralization of the Iron Core. Biochemistry 2004; 43: 4332-7.
46. Bou-Abdallah F, Carney E, Chasteen ND, Arosio P, Viescas AJ, Papaefthymiou GC. A Comparative Mössbauer Study of the Mineral Cores of Human H-Chain Ferritin Employing Dioxygen and Hydrogen Peroxide as Iron Oxidants. Biophys Chem 2007; 130(3): 114-21.
47. Bou-Abdallah GC, Papaefthymiou DM, Scheswohl SD, Stanga P, Arosio ND. Chasteen, mu-1,2-Peroxobridged di-iron(III) dimmer formation in human H-chain ferritin, Biochem. J 2002; 364: 57-63.
48. Zhao G, Bou-Abdallah F, Zrosil P, Levi S, Janus-Chandler C, Chasteen ND. Multiple pathways for mineral core formation in mammalian apoferritin. The role of hydrogen peroxide,Biochemistry 2003; 42: 3142-50.
49. Cassanelli S, Moulis J., Sulfide is an efficient iron releasing agent for mammalian ferritins. Biochim. Biophys. Acta 2001; 1547: 82-174.
50. Liu XS, Patterson LD, Miller MJ, Theil EC. Peptides selected for the protein nanocage pores change the rate of iron recovery from the ferritin minerál. J. Biol. Chem 2007; 282: 31821-5.
51. Jin W, Takali H, Pancorbo B, Theil EC. Opening the ferritin pore for iron release by mutation of conserved amino acids at interhelix and loop sites. Biochemistry 2001; 40: 7525-32.
52. Donovan A, Lima CA, Pinkus JL, Pinkus GS, Zon LI, Robine S, Andrews NC. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab 2005; 1: 191-200.
53. Yeh K, Yeh M, Mims L, Glass J: Iron feeding induces ferroportin 1 and hephaestin migration and interaction in rat duodenal epithe-lium. Am J Physiol Gastrointest Liver Physiol 2009; 296:65.
54. Harris ZL, Durley AP, Man TK, Gitlin JD. Targeted gene disrup-tion reveals an essential role for ceruloplasmin in cellular iron ef-flux. Proc Natl Acad Sci USA 1999; 96: 10812-7.
55. Gutteridge JM and Quinlan GJ. Antioxidant protection against organic and inorganic oxygen radicals by normal human plasma:the important primary role for iron-binding and iron-oxidising pro-teins. Biochim Biophys Acta 1992; 1159: 248-54.
56. Ohgami RS, Campagna DR, Greer EL, et al. Identification of a ferrireductase required for efficient transferrindependent iron uptake in erythroid cells. Nat Genet 2005; 37: 1264-9.
57. Andrews NC. Disorders of iron metabolism. New Eng J Med 2009; 341: 1986-95.
58. Canonne-Hergaux F, Donovan A, Delaby C, Wang HJ, Gros P: Comparative studies of duodenal and macrophage ferroportin pro-teins. Gastrointestinal and Liver Physiology 2006; 290(1): G156-63.
59. Delaby C, Pilard N, Gonçalves AS, Beaumont C, Canonne-Hergaux F. Presence of the iron exporter ferroportin at the plasma membrane of macrophages is enhanced by iron loading and down-regulated by hepcidin. Blood 2005; 106(12): 3979-84.
60. Ramey G, Deschemin JCH, Durel B, Canonne-Hergaux F, Nicolas G, Vaulont S. Hepcidin targets ferroportin for degradation in hepa-tocytes. Haematologica 2010; 95(3): 501-4.
61. Andriopoulos B Jr, Corradini E, Xia Y, et al. BMP6 is a key en-dogenous regulator of hepcidin expression and iron metabolism.Nat. Genet 2009; 41: 482-87.
62. Babitt JL, Huang FW, Wrighting DM, et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression.Nat. Genet 2006; 38: 531-9.
63. Silvestri L, Pagani A, Nai A, de Domenico I, Kaplan J, Cam-Aschella C., The serine protease matriptase-2 (TMPRSS6) inhibitshepcidin activation by cleaving membrane hemojuvelin. Cell Me-tab 2008; 8: 502-11.
64. Lin L, Goldberg YP, Ganz T.Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin. Blood 2005; 106: 2884-9.
65. Niederkofler V, Salie R, Arber S. Hemojuvelin is essential for dietary iron sensing, and its mutation leads to severe iron overload. J. Clin. Invest 2005; 115: 2180-6.
66. Kawabata H, Fleming RE, Gui D, et al. Expression of hepcidin is down-regulated in TfR2 mutant mice manifesting a phenotype of hereditary hemochromatosis. Blood 2005; 105: 376-81.
67. Papanikolaou G, Samuels ME, Ludwig EH, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat. Genet 2004; 36: 77-82.
68. Gao J, Chen J, Kamer M, Tsukamoto H, Zhang AS, Enns CA. Interaction of the hereditary hemochromatosis protein HFE with transferrin receptor 2 is required for transferrin-induced hepcidin expression. Cell Metab 2009; 9: 217-27.
69. Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002; 110: 1037-44.
70. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003; 101: 2461-63.
71. Valko M, Izakovic M, Mazur M, Rhodes CJ, Telser J. Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem. 2004; 266(1-2): 37-56.
72. Turrens JF. Mitochondrial formation of reactive oxygen species. J Physiol 2003; 552(Pt 2): 335-344.
73. Afanasev IB. Superoxide and Nitric Oxide in Pathological Condi-tions Associated with Iron Overload. The Effects of Antioxidants and Chelator. Curr Med Chem 2005; 12, 9-2731.
74. Halliwell B, Gutteridge JM. Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol 1990; 186: 1-85.
75. Buettner GR, Jurkiewicz BA. Catalytic metals, ascorbate and free radicals: combinations to avoid. Radiat Res 1996; 145(5): 532-41.
76. Duracková Z. Some current insights into oxidative stress. Physiol Res 2010; 59(4): 459-69.
77. Kakhlon O, Cabantchik ZI. The labile iron pool: characterization, measurement, and participation in cellular processes(1). Free Radic Biol Med 2002; 33(8): 1037-346.
78. Liochev SI, Fridovich I. The role of O2.- in the production of HO: In vitro and in vivo. Free Radic Biol Med 1994; 16(1): 29-33.
79. Huie RE, Padmaja S The reaction of NO with superoxide. Free Radic Res Commun 1993; 18: 195-9.
80. Gutteridge JM, Rowley DA, Halliwell B, Westermarck T. In- creased non-protein-bound iron and decreased protection againstsuperoxide-radical damage in cerebrospinal fluid from patients with neuronal ceroid lipofuscinoses. Lancet. 1982; 2(8296): 459-60.
81. Tuxworth RI, Chen H, Vivancos V, Carvajal N, Huang X, Tear G., The Batten disease gene CLN3 is required for the response to oxi-dative stress. Hum Mol Genet. 2011; 20(10): 2037-47.
82. Bush AI. The metallobiology of Alzheimer's disease. Trends Neu- rosci. 2003; 26(4): 207-14.
83. Bush AI, Curtain CC. Twenty years of metallo-neurobiology: where to now? Eur Biophys J 2008; 37(3): 241-5.
84. Rajendran R, Minqin R, Ynsa MD, et al. A novel approach to the identification and quantitative elemental analysis of amyloid depos-its-insights into the pathology of Alzheimer's disease. Biochem Biophys Res Commun 2009; 382(1): 91-5.
85. Dröge W., Free radicals in the physiological control of cell function. Physiol Rev. 2002; 82(1): 47-95.
86. Amit T, Avramovich-Tirosh Y, Youdim MB, Mandel S. Targeting multiple Alzheimer's disease etiologies with multimodal neuropro-tective and neurorestorative iron chelators. FASEB J. 2008; 22(5):1296-305.
87. Butterfield DA, Boyd-Kimball D. The critical role of methionine 35 in Alzheimer's amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity. Biochim Biophys Acta 2005; 1703(2): 149-56.
88. Schoneich C, Pogocki D, Hug GL, Bobrowski K. Free radical reactions of methionine in peptides: mechanisms relevant to beta-amyloid oxidation and Alzheimer's disease. J Am Chem Soc 2003; 125: 13700-13.
89. da Silva GF, Lykourinou V, Angerhofer A, Ming LJ. Methionine does not reduce Cu(II)-beta-amyloid!-rectification of the roles of methionine-35 and reducing agents in metal centered oxidation chemistry of Cu(II)-beta-amyloid. Biochim Biophys Acta 2009; 1792: 49-55.
90. Butterfield DA, Sultana R., Methionine-35 of A (1-42): Importance for Oxidative Stress in Alzheimer Disease. Journal of Amino Acids ID 198430, 2011.
91. Premkumar DR, Smith MA, Richey PL, et al. Induction of heme oxygenase-1 mRNA and protein in neocortex and cerebral vessels in Alzheimer's disease. J Neurochem. 1995; 65(3): 1399-402.
92. Moreira PI, Sayre LM, Zhu X, Nunomura A, Smith MA, Perry G. Detection and localization of markers of oxidative stress by in situ methods: application in the study of Alzheimer disease. Methods Mol Biol. 2010; 610: 419-34.
93. Jomova K, Vondrakova D, Lawson M, Valko M. Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem 2010; 345(1-2): 91-104.
94. Eriksen J, Dawson T, Dickson D, Petrucelli L Caught in the act: a- synuclein is the culprit in Parkinson's disease. Neuron 2003; 40:453-6.
95. Gasser T Genetics of Parkinson's disease. J Neurol 2001; 248: 833-40.
96. Bhidayasiri R, Truong DD. Chorea and related disorders. Postgrad Med J 2004; 80(947): 527-34.
97. Bauer PO, Nukina N. The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. J Neurochem 2009; 110(6): 1737-65.
98. Atkinson A, Winge DR. Metal acquisition and availability in the mitochondria. Chem Rev 2009; 109(10): 4708-21.
99. Babady NE, Carelle N, Wells RD, et al., Advancements in the pathophysiology of Friedreich's Ataxia and new prospects for treatments. Mol Genet Metab 2007; 92(1-2): 23-35.
100. Anderson PR, Kirby K, Hilliker AJ, Phillips JP. RNAimediated suppression of the mitochondrial iron chaperone, frataxin, in Drosophila. Hum Mol Genet 2005; 14(22): 3397-405.
101. Huang ML, Becker EM, Whitnall M, Rahmanto YS, Ponka P, Richardson DR. Elucidation of the mechanism of mitochondrial iron loading in Friedreich's ataxia by analysis of a mouse mutant. Proc Natl Acad Sci USA 2009; 106(38): 16381-6.
102. Bailey DM, Robach P, Thomsen JJ, Lundby C. Erythropoietin depletes iron stores: antioxidant neuroprotection for ischemic stroke? Stroke 2006; 37(10): 2453
103. Adams CWM. Perivascular iron deposition and other vascular damage in multiple sclerosis. J Neurol Neurosurg Psychiatry 1988; 51(2): 260-5.
104. Sayre LM, Moreira PI, Smith MA, Perry G. Metal ions and oxidative protein modification in neurological disease. Ann Ist Super Sanita 2005; 41(2): 143-64.
105. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radi- cals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 2006; 160(1): 1-40.
106. Shigenaga MK, Gimeno CJ, Ames BN. Urinary 8-hydroxy-2'- deoxyguanosine as a biological marker of in vivo oxidative DNA damage. Proc Natl Acad Sci USA 1989; 86(24): 9697-701.
107. Dizdaroglu M, Jaruga P, Birincioglu M, Rodriguez H. Free radical-induced damage to DNA: mechanisms and measurement. Free Radic Biol Med. 2002; 32(11): 1102-15.
108. England TG, Jenner A, Aruoma OI, Halliwell B. Determination of oxidative DNA base damage by gas chromatography-mass spec-trometry. Effect of derivatization conditions on artifactual forma-tion of certain base oxidation products. Free Radic Res. 1998; 29(4): 321-30.
109. Marnett LJ. Oxyradicals and DNA damage. Carcinogenesis. 2000; 21(3): 361-70.
110. Marnett LJ. Lipid peroxidation-DNA damage by malondialdehyde. Mutat Res. 1999; 424(1-2): 83-95.
111. Stadtman ER. Role of oxidant species in aging. Curr Med Chem. 2004; 11(9): 1105-12.
112. Sun Y, Oberley LW, Redox regulation of transcriptional activators. Free Radic Biol Med 1996; 21: 335-48.
113. Hsu TC, Young MR, Cmarik J, Colburn NH, Activator protein 1 (AP-1)- and nuclear factor kappa B (NF-kappa B)-dependent tran-scriptional events in carcinogenesis. Free Radic Biol Med 2000; 28:1338-48.
114. Pinkus R, Weiner LM, Daniel V. Role of oxidants and antioxidants in the induction of AP-1, NF-kappa B, and glutathione S-transferase gene expression. J. Biol Chem 1996; 271: 13422-9.
115. Knight JA, Free radicals, antioxidants, and the immune system,Ann Clin Lab Sci 2000; 30: 145-8.
116. Hughes G, Murphy MP, Ledgerwood EC, Mitochondrial reactive oxygen species regulate the temporal activation of nuclear factor kappa B to modulate tumour necrosis factor-induced apoptosis: evidence from mitochondria-targeted antioxidants. Biochem J 2005; 389: 83-9.
117. Orange JS, Levy O, Geha RS. Human disease resulting from gene mutations that interfere with appropriate nuclear factor-kappa B ac-tivation. Immunol Rev 2005; 203: 21-37.
118. Toyokuni S., Iron-induced carcinogenesis: The role of redox regula- tion. Free Radic Biol Med 1996; 20(4): 66-553.
119. Babbs CF, Free-radicals and the etiology of colon cancer, Free Radic Biol Med 1990; 8: 191-200.
120. Valko M, Morris H, Mazúr M, Rapta P, Bilton RF. Oxygen free radical generating mechanisms in the colon: do the semiquinones of vitamin K play a role in the aetiology of colon cancer? Biochim Biophys Acta 2001; 1527(3): 161-6.
121. Zhou W, Park S, Liu G, et al. Dietary iron, zinc, and calcium and the risk of lung cancer. Epidemiology. 2005; 16(6): 772-9.
122. ATBC trial. Cigarette Smoke or Alcohol Consumption May En-hance adverse Effects of Beta Carotene in Vitamin Prevention Tri-als, National Institute of Health, National Cancer Institute 1996.
123. Pinnix ZK, Miller LD, Wang W, et al. Ferroportin and iron regula- tion in breast cancer progression and prognosis. Sci Transl Med 2010; 2(43): 43-56.
124. Torti SV, Torti FM. Ironing out cancer. Cancer Res 2011; 71(5): 1511-4.
125. Ahn J. Genetic Variability in Iron-Related Oxidative Stress Path-ways (Nrf2, NQ01, NOS3, and HO-1), Iron Intake, and Risk of Postmenopausal Breast Cancer. Cancer Epidemiol Biomarkers Prev 2007; 16: 1784-94.
126. Dinkova-Kostova AT, Talalay P. NAD(P)H: quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. Arch Biochem Biophys 2010; 501(1): 116-23.
127. Eldor A, Rachmilewitz EA. The hypercoagulable state in thalas-semia. Blood. 2002; 99(1): 36-43.
128. Naithani R, Chandra J, Bhattacharjee J, Verma P, Narayan S. Peroxidative stress and antioxidant enzymes in children with beta-thalassemia major. Pediatr Blood Cancer. 2006; 46(7): 780-5.
129. Grinberg LN, Rachmilewitz EA, Kitrossky N, Chevion M. Hy- droxyl radical generation in beta-thalassemic red blood cells. Free Radic Biol Med. 1995; 18(3): 611-5.
130. Du W, Adam Z, Rani R, Zhang X, Pang Q. Oxidative stress in Fanconi anemia hematopoiesis and disease progression. Antiox Redox Signal 2008; 10(11): 1909-21.
131. Drechsel H, Jung G. Peptide siderophores. J Pept Sci. 1998; 4(3): 147-81.
132. Welch KD, Davis TZ, Van Eden ME, Aust SD. Deleterious iron-mediated oxidation of biomolecules. Free Radic Biol Med 2002;32(7): 577-83.
133. Miller DM, Buettner GR, Aust SD. Transition metals as catalysts of autoxidation reactions. Free Radic Biol Med 1990; 8(1): 95-108.
134. Chaston TB, Richardson DR. Iron chelators for the treatment of iron overload disease: relationship between structure, redox activ- ity, and toxicity. Am J Hematol 2003; 73(3): 200-10.
135. Chiani MA, Akbarzadeh A, Farhangi M, Mazinani Z, Saffari K, Emadzadeh MR. Mehrabi, Optimization of culture medium to in-crease the production of desferrioxamine B (desferal) in Streptomy-ces pilosus. Pak J Biol Sci 2010; 13: 546-50.
136. Neilands JB. Microbial iron compounds. Annu Rev Biochem 1981;50: 715-31.
137. Le CT, Hollaar L, Van der Valk EJ, Van der Laarse A. Desferriox-amine protects myocytes against peroxide-induced myocyte dam-age without affecting glutathione redox cycle turnover. J Mol Cell Cardiol 1994; 26(7): 877-87.
138. Goncalves S, Paupe V, Dassa EP, Rustin P. Deferiprone targets aconitase: Implication for Friedreich's ataxia treatment BMC Neu-rology 2008, 8: 20
139. Hider RC, Ma Y, Molina-Holgado F, Gaeta A, Roy S. Iron chela- tion as a potential therapy for neurodegenerative disease. Biochem Soc Trans 2008; 36(Pt 6): 1304-8.
140. Bush AI. Drug development based on the metals hypothesis of Alzheimer's disease. J Alzheimers Dis 2008; 15: 223-40.
141. Shiraki H: The neuropathology of subacute myelo-optico-neuropathy, SMON, in the humans: -with special reference to the quinoform intoxication. Jpn J Med Sci Biol 1975; 28(Suppl): 101-64.
142. Arbiser JL, Kraeft SK, van Leeuwen R, et al. Clioquinol-zinc chelate: a candidate causative agent of subacute myelo-optic neu- ropathy. Mol Med 1998; 4: 665-70.
143. Shachar DB, Kahana N, Kampel V, Warshawsky A, Youdim MB. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacology. 2004; 46(2): 254-63.
144. Whitnall M, Howard J, Ponka P, Richardson DR: A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci USA 2006; 103: 14901-6.
145. Mello Filho AC, Hoffmann ME, Meneghini R. Cell killing and DNA damage by hydrogen peroxide are mediated by intracellular iron. Biochem J 1984; 218: 273-5.
146. Kalinowski DS, Yu Y, Sharpe PC, et al. Design synthesis, and characterization of novel iron chelators: structure-activity relation-ships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents. J Med Chem 2007; 50: 3716-29.
147. Kalinowski DS, Sharpe PC, Bernhardt PV, Richardson DR., Design Synthesis, and Characterization of New Iron Chelators with Anti-Proliferative Activity: Structure-Activity Relationships of Novel Thiohydrazone Analogues. J Med Chem 2007; 50: 25-6212.
148. Bush AI. Metal complexing agents as therapies for Alzheimer's disease. Neurobiology of Aging 2002, 23: 1031-8.
149. Youdim MBH, Fridkin M, Zheng H. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neu-rodegenerative diseases. J Neural Transmission 2004; 111: 1455-71.
150. Horwitz LD, Sherman NA, Kong YN, et al. Lipophilic sideropho- res Mycobacterium tuberculosis prevent cardiac reperfusion injury. Proc Natl Acad Sci 1998; 95: 5263-8.
151. De Vries B, Walter SJ, Von Bonsdorff L, et al. Reduction of circu- lating redox-active iron by apotransferrin protects against renal ischemia-reperfusion injury. Transplantation 2004; 77: 669-75.
152. Kontoghiorghes GJ., Iron mobilization from transferrin and non- transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other condi- tions. Hemoglobin 2006; 30: 183-200.
153. Pierre JL, Baret P, Serratrice G: Hydroxyquinolines as iron chela- tors. Curr Med Chem 2003; 10: 1077-84.
154. Tesoriere L, Arpa D, Butera D, et al. Oral supplements of vita-min E improve measures of oxidative stress in plasma and reduce oxidative damage to LDL and erythrocytes in beta-thalassemia in-termedia patients. Free Radic Res 2001; 34(5): 529-40.
155. Mandel S, Amit T, Bar-Am O, Youdim MB. Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precur-sor protein-processing regulatory activities as therapeutic agents. Prog Neurobiol 2007; 82: 348-60.
156. Morel I, Lescoat G, Cogrel P, et al. Antioxidant and iron-chelating activities of the flavonoids catechin, quercetin and diosmetin on iron-loaded rat hepatocyte cultures. Biochem Pharmacol 1993; 45: 13-9.
157. Afanas'ev IB, Dorozhko AI, Brodskii AV, Kostyuk VA, Pota- povitch AI: Chelating and free radical scavenging mechanisms of inhibitory action of rutin and quercetin in lipid peroxidation. Bio-chem Pharmacol 1989; 38: 1763-9.
158. Zhang HY, Yang DP, Tang GY. Multipotent antioxidants: from screening to design. Drug Discov Today 2006; 11: 749-54.
159. Engelmann MD, Hutcheson R, Cheng IF. Stability of ferric com-plexes with 3-hydroxyflavone (flavonol), 5,7-dihydroxyflavone (chrysin), and 3', 4'-dihydroxyflavone. J Agric Food Chem 2005; 53: 2953-60.
160. Rice-Evans CA, Miller J, Paganga G. Antioxidant properties of phenolic compounds. Trends in Plant Science 1997; 2: 152-9.
161. Butelli E, Titta L, Giorgio M, et al. Enrichment of tomato fruit with health-promoting anthocyanins by expression of select transcription factors. Nat Biotechnol 2008; 26: 1301-8.
162. Kelloff GJ, Crowell JA, Steele VE, et al. Progress in cancer che-moprevention: development of diet-derived chemopreventive agents. J Nutr 2000; 130: 467S-71S.
163. Russo GL: Ins and outs of dietary phytochemicals in cancer che- moprevention. Biochem Pharmacol 2007; 74: 533-44.
164. Wang JY, Wen LL, Huang YN, Chen YT, Ku MC. Dual effects of antioxidants in neurodegeneration: direct neuroprotection against oxidative stress and indirect protection via suppression of glia-mediated inflammation. Curr Pharm Des 2006; 12(27): 3521-33.